Shuang Zhang,Jingjing Liu,Hui Li,Ying Cheng. Anti-angiogenesis in lung cancer therapy: the shore and the other shore. Oncol Transl Med, 2015, 1: 15-19.
Anti-angiogenesis in lung cancer therapy: the shore and the other shore
Received:December 31, 2014  Revised:February 02, 2015
View Full Text  View/Add Comment  Download reader
KeyWord:angiogenesis; non-small cell lung cancer (NSCLC)
Author NameAffiliationE-mail
Shuang Zhang Department of Thoracic Oncology,Jilin Provincial Cancer Hospital zhangshuangphy@126.com 
Jingjing Liu Department of Thoracic Oncology,Jilin Provincial Cancer Hospital jingjingstone@126.com 
Hui Li Department of Thoracic Oncology,Jilin Provincial Cancer Hospital zhangshuangphy@126.com 
Ying Cheng Department of Thoracic Oncology,Jilin Provincial Cancer Hospital jl.cheng@163.com 
Hits: 6785
Download times: 8551
Abstract:
      Angiogenesis is known to be an important event in tumor growth. In preclinical and clinical researches, anti-angiogenesis therapy has made great progress, but there are still many problems for future anti-angiogenesis therapy. Here, we review recently completed clinical trials of emerging antiangiogenic agents in patients with non-small cell lung cancer (NSCLC) and discuss the challenges of anti-angiogenic therapy.
Close